Get started
RocketTickers

U.S. FDA Approves VIZIMPRO® (dacomitinib)

Long
Pfizer (NYSE:PFE)  
RocketTickers  
NYSE:PFE   Pfizer
Beyond Technical Analysis
2
1
beyondta
PFE: Pfizer Inc.
2018-09-27 17:41:00
U.S. FDA Approves VIZIMPRO® (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.